GlassScriptPhysician profile
Reema Aljamal
NPI 1316434830
$2,411.45
in general payments reported to CMS, 2019-2025
15 companies · $857 in 2025
The $857 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $296 · 2022: $269 · 2023: $503 · 2024: $487 · 2025: $857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,806 · Travel and Lodging: $40.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,806.14 |
| Travel and Lodging | $40.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,018.95 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $364.10 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $266.11 | 2021-2025 | |
| Glaxosmithkline, LLC. | $144.68 | 2022-2025 | Arexvy, Shingrix |
| Abiomed | $114.77 | 2021 | |
| Exact Sciences Corporation | $109.50 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $93.76 | 2023-2025 | Otezla, Repatha, Otezla |
| Artivion, INC. | $74.87 | 2023 | Cardiac Non-Synergraft |
| Lilly USA, LLC | $56.81 | 2024-2025 | Mounjaro, Zepbound |
| Genentech USA, INC. | $55.85 | 2021-2022 | |
| Gilead Sciences, INC. | $34.52 | 2025 | |
| Astellas Pharma US INC | $23.16 | 2024 | Veozah |
| Merck Sharp & Dohme LLC | $21.94 | 2024 | Lagevrio |
| Phadia US INC. | $18.11 | 2023 | Immunocap |
| Vbi Vaccine (Delaware) INC. | $14.32 | 2023 | Prehevbrio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reema Aljamal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.